Indaptus Therapeutics, Inc. announced the launch of a new social media initiative to provide education and updates about the company. Recognizing the importance of engaging with all stakeholders, Indaptus will generate content on a variety of digital platforms, including X (formerly known as Twitter) and LinkedIn. Indaptus Therapeutics emerges from over a century of groundbreaking advancements in immunotherapy and has built an approach that is designed to stimulate a broad acting effect on the immune system to combat some of the most difficult types of cancer.

At the core of Indaptus' patented technology are single strains of proprietary killed, non-pathogenic bacteria that can activate cellular immune pathways in the fight against cancer and viral infections. The company is currently advancing its innovative immunotherapy for the treatment of solid metastatic tumors in Phase 1 human trials. The launch of these channels signifies Indaptus Therapeutics' commitment to transparency, knowledge-sharing, and a desire to stay connected with its stakeholders. The company will utilize these platforms to provide updates on its research, share educational content about cancer immunotherapy, and offer a behind-the-scenes look at its team and scientific progress.

The company invites all interested parties, including patients, researchers, and the general public, to join the conversation and stay informed about the company?s promising strides in cancer and viral infection treatment.